U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CO3.2Al.6Mg.9O.12H2O
Molecular Weight 619.9799
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge -2

SHOW SMILES / InChI
Structure of HYDROTALCITE

SMILES

O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O

InChI

InChIKey=BEBILBPAQKONJS-UHFFFAOYSA-L
InChI=1S/CH2O3.2Al.6Mg.12H2O.9O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;;;12*1H2;;;;;;;;;/q;2*+3;6*+2;;;;;;;;;;;;;9*-2/p-2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Al
Molecular Weight 26.9815
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Mg
Molecular Weight 24.305
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH2O3
Molecular Weight 62.0248
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/algeldrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18362170 | https://www.ncbi.nlm.nih.gov/pubmed/12222737 | https://www.ncbi.nlm.nih.gov/pubmed/9115023 | https://www.ncbi.nlm.nih.gov/pubmed/15479434

Algeldrate (Aluminium hydroxide) is the amphoteric inorganic compound used as an antacid in the treatment of Duodenal, Peptic and Stomach Ulcer and some other conditions. Aluminium hydroxide is preferred over other alternatives such as sodium bicarbonate because Al(OH)3, being insoluble, does not increase the pH of stomach above 7 and hence, does not trigger secretion of excess acid by the stomach. Brand names include Alu-Cap, Aludrox, Gaviscon or Pepsamar. It reacts with the excess acid in the stomach, reducing the acidity of the stomach content, which may relieve the symptoms of ulcers, heartburn or dyspepsia. Such products can cause constipation, because the aluminum ions inhibit the contractions of smooth muscle cells in the gastrointestinal tract, slowing peristalsis and lengthening the time needed for stool to pass through the colon. Some such products (such as Maalox) are formulated to minimize such effects through the inclusion of equal concentrations of magnesium hydroxide or magnesium carbonate, which have counterbalancing laxative effects. This compound is also used to control phosphate (phosphorus) levels in the blood of people suffering from kidney failure. Precipitated aluminum hydroxide is included as an adjuvant in some vaccines (e.g. anthrax vaccine). One of the well-known brands of aluminum hydroxide adjuvant is Alhydrogel, made by Brenntag Biosector. Since it absorbs protein well, it also functions to stabilize vaccines by preventing the proteins in the vaccine from precipitating or sticking to the walls of the container during storage. Aluminium hydroxide is sometimes mistakenly called "alum", which properly refers to aluminum potassium sulfate. Vaccine formulations containing aluminum hydroxide stimulate the immune system by inducing the release of uric acid, an immunological danger signal. This strongly attracts certain types of monocytes which differentiate into dendritic cells. The dendritic cells pick up the antigen, carry it to lymph nodes, and stimulate T cells and B cells. It appears to contribute to induction of a good Th2 response, so is useful for immunizing against pathogens that are blocked by antibodies. In the 1960s and 1970s, it was speculated that aluminum was related to various neurological disorders including Alzheimer's disease. Since then, multiple epidemiological studies have found no connection between exposure to aluminum and neurological disorders.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Alhydrogel

Approved Use

Unknown
Primary
Gelusil-Lac

Approved Use

Unknown
Primary
Gastracid

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Quartz exposure of the rat lung leads to a linear dose response in inflammation but not in oxidative DNA damage and mutagenicity.
2001 Apr
The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation.
2004 Aug
Comparison of the response of primary human blood monocytes and the U937 human monocytic cell line to two different sizes of alumina ceramic particles.
2004 Jul
Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles.
2005 May
Large aqueous aluminum hydroxide molecules.
2006 Jan
Microdermabrasion with and without aluminum oxide crystal abrasion: a comparative molecular analysis of dermal remodeling.
2006 Mar
Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation.
2009 Feb
The effects of implant surface nanoscale features on osteoblast-specific gene expression.
2009 Sep
Aluminum nanoparticle exposure in L1 larvae results in more severe lethality toxicity than in L4 larvae or young adults by strengthening the formation of stress response and intestinal lipofuscin accumulation in nematodes.
2011 Jan
In vivo toxicity of nano-alumina on mice neurobehavioral profiles and the potential mechanisms.
2011 Jan-Mar
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Al₂O₃ nanoparticles induce mitochondria-mediated cell death and upregulate the expression of signaling genes in human mesenchymal stem cells.
2012 Nov
Atomic layer deposition coating of carbon nanotubes with aluminum oxide alters pro-fibrogenic cytokine expression by human mononuclear phagocytes in vitro and reduces lung fibrosis in mice in vivo.
2014
Toxicoproteomic analysis of pulmonary carbon nanotube exposure using LC-MS/MS.
2015 Mar 2
Patents

Patents

Sample Use Guides

Adults and children over 15 years: 1-2 table (400-800ьп). 4 times a day 1 hour after meals and in the evening before bed or if there is discomfort, epigastric pain, heartburn.
Route of Administration: Oral
Bone marrow cells were cultured for 9 d in dendritic cells (DC) culture medium (DC-CM; RPMI 1640 containing GlutaMAX-I; Invitrogen) supplemented with 5% (vol/vol) FCS (Sigma-Aldrich), 50 μ M 2-mercaptoethanol (Sigma-Aldrich), 50 μ g/ml gentamicin (Invitrogen), and 20 ng/ml recombinant mouse GM-CSF (a gift from K. Thielemans, Vrije Universiteit Brussel, Brussels, Belgium). 16 h before harvesting, DCs were exposed either to 10 μ g/ml of OVA, alum (Algeldrate), or OVA-alum suspension.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:57:40 UTC 2023
Edited
by admin
on Fri Dec 15 17:57:40 UTC 2023
Record UNII
17432CG1KU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROTALCITE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
hydrotalcite [INN]
Common Name English
TALCID
Brand Name English
Hydrotalcite [WHO-DD]
Common Name English
HYDROTALCITE [MI]
Common Name English
ALTACITE
Brand Name English
NACID
Brand Name English
HYDROTALCITE [MART.]
Common Name English
HI-TI
Brand Name English
HYDROTALCITE [JAN]
Common Name English
Classification Tree Code System Code
Food Contact Sustance Notif, (FCN No.) FCN NO. 633
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
WHO-ATC A02AD04
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
WHO-VATC QA02AD04
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
Food Contact Sustance Notif, (FCN No.) FCN NO. 193
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
Code System Code Type Description
DRUG BANK
DB13322
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
MESH
C010467
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
PUBCHEM
73415812
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
CAS
454465-31-7
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
ALTERNATIVE
MERCK INDEX
m6994
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY Merck Index
CAS
12304-65-3
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
INN
2841
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
RXCUI
27221
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY RxNorm
EVMPD
SUB08071MIG
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
NCI_THESAURUS
C166469
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
SMS_ID
100000084217
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
DAILYMED
17432CG1KU
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
FDA UNII
17432CG1KU
Created by admin on Fri Dec 15 17:57:41 UTC 2023 , Edited by admin on Fri Dec 15 17:57:41 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY